北京商报讯（记者 王寅浩 宋雨盈）12月17日，同仁堂发布公告，对近期关于"北京同仁堂99%高纯南极 磷虾油"涉嫌造假的相关报道进行说明并予以澄清。 公告称，同仁堂未直接或间接持有南极磷虾油相关报道中提及的四川健康药业任何股权及投资权益，四 川健康药业不属于本公司下属子企业。 但公告也承认，四川健康药业为公司控股股东中国北京同仁堂（集团）有限责任公司（以下简称"同仁 堂集团"）下属北京同仁堂健康药业股份有限公司（以下简称"同仁堂健康"）的控股子公司。 公告强调，"同仁堂"商标和"同仁堂""北京同仁堂"字号的所有人为同仁堂集团。公司及部分子公司获同 仁堂集团许可，在商品上使用该商标并用于公司商号。截至本公告披露日，同仁堂药品均为自主生产， 不存在委托外部第三方生产的情况。 ...

Core Viewpoint - Beijing Tongrentang Co., Ltd. issued a clarification announcement regarding misleading media reports about a product labeled as "99% high-purity Antarctic krill oil" linked to its brand, emphasizing that it does not hold any equity or investment rights in the involved distributor, Sichuan Health Pharmaceutical Co., Ltd. [1][6] Group 1: Company Response - The company has ordered Sichuan Health Pharmaceutical to cease distribution of the implicated product and initiated a full process review and traceability of the product [2] - Legal action has been initiated against the involved companies to protect consumer rights and the company's brand integrity [2][7] - The product in question was found to contain "0" krill oil, despite claims of high purity, leading to significant consumer deception [1][5] Group 2: Brand and Product Integrity - The packaging of the product misleadingly emphasized the "Beijing Tongrentang" name, creating confusion about its actual manufacturer [5] - The company clarified that it does not produce or authorize the production of the Antarctic krill oil product in question, and all its products are produced in-house [6][7] - The company has a diverse portfolio of over 400 traditional Chinese medicine products, which supports its brand development and operational stability [6] Group 3: Financial Performance - For Q3, the company reported revenue of 3.539 billion yuan, a year-on-year decline of 12.76%, with a net profit of 232 million yuan, down nearly 30% [7] - For the first three quarters, total revenue reached 13.308 billion yuan, a decrease of 3.7%, with a net profit of 1.178 billion yuan, down 12.78% [7] - As of December 17, the company's stock price closed at 32.57 yuan, down 0.82% [8]

Core Viewpoint - The Shanghai Consumer Protection Committee has exposed the "Tongrentang Antarctic Krill Oil" product for having a phospholipid content of 0, raising serious questions about the integrity of the brand and its suppliers [1] Group 1: Product Issues - The Shanghai Consumer Protection Committee published an article questioning the authenticity of the Antarctic krill oil product, highlighting concerns about potential fraud and the responsibilities of those involved [1] - Consumers are purchasing the product at a price of 50-60 yuan per bottle, while the procurement cost is only 3-4 yuan, indicating a significant markup without any actual krill oil content [1] Group 2: Company Accountability - The product in question, labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil," was produced by Anhui Hab Pharmaceutical Co., Ltd., with Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. as the distributor [1] - During discussions, the distributor, Beijing Tongrentang (Sichuan), avoided addressing the issue and claimed ignorance regarding the alleged fraudulent activities, distancing themselves from the situation [1]

Group 1 - Company X plans to invest in the research and production of optical modules, focusing on ultra-low power consumption chips for high-end applications such as AI computing centers [1] - CICC is planning to absorb and merge with Dongxing Securities and Xinda Securities through a share swap, with stock trading resuming on December 18, 2025 [2] - Bona Film Group reports normal operations and has invested in multiple films for the upcoming holiday seasons, including major productions [3] Group 2 - Tongrentang clarifies it does not hold any equity or investment rights in Sichuan Health Pharmaceutical, which is associated with a product mentioned in recent reports [4] - Meike Home is planning to acquire control of Shenzhen Wandeling Technology through a combination of cash and stock issuance, with trading suspended for up to 10 days [5] - Lanhua Ketech has obtained a coal exploration license for a specific area, laying the groundwork for future mining rights [6] Group 3 - China Duty Free Group's subsidiary has signed contracts for duty-free store operations at major Shanghai airports [7] - Baida Group's stock has seen a significant increase of 61.1% in a short period, raising concerns about potential rapid declines [8] - Changyuan Power's subsidiary has successfully connected a new power generation unit to the grid, marking its commercial operation [9] Group 4 - Guangdong Construction has launched two clean energy projects, contributing to a total installed capacity of 5084.52 MW across various energy sources [10] - Shanghai Airport has signed contracts for duty-free store operations, which are expected to positively impact future revenues [11] - Aokeli's subsidiary has entered trial production for a special high-temperature resistant resin project, aligning with its strategic goals in aerospace [12] Group 5 - China Nuclear Engineering has reported cumulative revenue of 92.03 billion yuan as of November 2025 [13] - Zhaobiao Co. plans to reduce its stake by up to 3% through various trading methods [14] - Shengtai Group's major shareholder intends to reduce its stake by up to 3% [15] Group 6 - Xinyi Co. plans to reduce its stake by up to 1% due to personal asset allocation needs [16] - Nanjing Bank intends to fully redeem 49 million preferred shares on December 23, 2025 [17] - Huakai Yibai plans to repurchase shares worth between 15 million and 30 million yuan for employee incentives [18] Group 7 - China Metallurgical Group plans to repurchase A-shares worth between 1 billion and 2 billion yuan [19] - A director of Gao Neng Environment has increased his stake by purchasing 56,100 shares [20] - Jiayuan Technology's shareholders plan to transfer 3.24 million shares, representing 2.51% of the total share capital [21] Group 8 - Pubang Co. has been awarded a construction project for Xiangmi Lake Park with a bid of 333 million yuan [22] - China CRRC has signed contracts totaling approximately 53.31 billion yuan, representing 21.6% of its projected revenue for 2024 [23][24] - Pudong Construction's subsidiaries have won multiple projects totaling 1.649 billion yuan [25] Group 9 - Pingzhi Information's subsidiary has signed a 38.25 million yuan computing service contract with a telecommunications company [26]

Core Viewpoint - The company clarifies that it does not hold any direct or indirect equity or investment rights in Sichuan Health Pharmaceutical Co., Ltd., which is involved in the production and distribution of Antarctic krill oil products associated with the "Tong Ren Tang" brand [1] Group 1 - The company has noted reports regarding the Antarctic krill oil products produced by Anhui Habao Pharmaceutical Co., Ltd. and distributed by Beijing Tong Ren Tang (Sichuan) Health Pharmaceutical Co., Ltd. [1] - The company confirms that Sichuan Health Pharmaceutical is not a subsidiary of the company but a holding subsidiary of Tong Ren Tang Group, the company's controlling shareholder [1] - The company is actively communicating with Tong Ren Tang Group to address the situation and jointly maintain the brand image and reputation of "Tong Ren Tang" [1] Group 2 - Tong Ren Tang Group is urging Tong Ren Tang Health to handle the situation in accordance with the law [1] - As of the date of the announcement, the company's medicines are all self-produced, and there is no situation of outsourcing production to external third parties [1]

证券代码：600085 证券简称： 同仁堂 公告编号：2025-041 北京同仁堂股份有限公司 关于相关媒体报道的澄清公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 一、 事件简述 近日，北京同仁堂股份有限公司（以下简称公司或本公司）关注到网络上有关 于安徽哈博药业有限公司生产、北京同仁堂（四川）健康药业有限公司（以下简称 四川健康药业）经销的一款南极磷虾油产品及相关对"同仁堂"品牌的报道。 为避免相关报道对投资者造成误导，公司针对上述事项进行说明并予以澄清。 二、 澄清说明 （一） 关于"同仁堂"商标、字号权属及使用情况 本公司未直接或间接持有南极磷虾油相关报道中提及的四川健康药业任何股 权及投资权益，四川健康药业不属于本公司下属子企业。四川健康药业为公司控股 股东中国北京同仁堂（集团）有限责任公司（以下简称同仁堂集团）下属北京同仁 堂健康药业股份有限公司（以下简称同仁堂健康）的控股子公司。 "同仁堂"商标和"同仁堂"、"北京同仁堂"字号的所有人为同仁堂集团。 本公司及本公司部分子公司获同仁堂集团许可，在商品上使用该商 ...

Core Viewpoint - Tong Ren Tang (600085.SH) issued a statement to clarify its non-involvement with a product related to Antarctic krill oil and to address misleading reports regarding the "Tong Ren Tang" brand [1][2] Group 1: Company Clarification - The company does not hold any direct or indirect equity or investment rights in Sichuan Health Pharmaceutical, which is involved in the production and distribution of the Antarctic krill oil product [1] - Sichuan Health Pharmaceutical is a subsidiary of Beijing Tong Ren Tang Health Pharmaceutical Co., Ltd., which is controlled by the company's major shareholder, Tong Ren Tang Group [1] - The "Tong Ren Tang" trademark and name are owned by Tong Ren Tang Group, which has licensed the use of the trademark to the company and some of its subsidiaries [1] Group 2: Brand Protection Efforts - The company has actively communicated with Tong Ren Tang Group to understand the situation and jointly protect the brand image and reputation [2] - Tong Ren Tang Group is urging Tong Ren Tang Health to handle the situation in accordance with the law [2]

Core Viewpoint - The article highlights the issue of counterfeit products using the "Beijing Tongrentang" brand, specifically a shrimp oil product falsely marketed as having high purity but containing no actual shrimp oil. This situation raises concerns about brand integrity and consumer protection in the e-commerce space [1]. Group 1: Brand Integrity and Consumer Trust - A product claiming to be "Beijing Tongrentang 99% high purity Antarctic shrimp oil" was found to contain 0% shrimp oil, misleading consumers who associate the brand with quality [1]. - The product was sold in large quantities, with reports indicating 5 million units sold on e-commerce platforms, showcasing the scale of the issue [1]. - The company, Beijing Tongrentang Health Pharmaceutical Co., Ltd., has initiated legal action against the infringing company, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., to protect its brand reputation [1]. Group 2: Regulatory and Management Concerns - The infringing company claims ignorance regarding the misleading packaging, attributing the decision to the manufacturer, Anhui Habao Pharmaceutical Co., Ltd., which has a history of administrative penalties for non-compliance [1]. - The manufacturer’s pricing strategy, with an ex-factory price significantly lower than reasonable cost estimates, raises questions about the legitimacy of the product and the awareness of the infringing company [1]. - The article emphasizes the need for better brand management and quality control within the parent company, as the infringing entity is a subsidiary, indicating potential flaws in oversight [1]. Group 3: E-commerce and Market Regulation - The article describes a chaotic "Tongrentang universe" in e-commerce, where various products mislead consumers by prominently displaying the "Beijing Tongrentang" name while being produced by unrelated companies [1]. - It calls for stronger regulatory measures to protect consumers and uphold the integrity of established brands, suggesting that both the brand owner and regulatory bodies must work together to combat counterfeit products [1]. - The ongoing issue of counterfeit products in the market, including those imitating other reputable brands, highlights the need for vigilance and proactive measures to safeguard consumer rights [1].

Core Viewpoint - Tongrentang issued a clarification announcement regarding online reports about its Antarctic krill oil products and related brand situations, emphasizing that it does not hold any equity or investment rights in Sichuan Health Pharmaceutical, which is not a subsidiary of Tongrentang but rather a part of its controlling shareholder, Tongrentang Group [1] Group 1 - Tongrentang clarified that it does not directly or indirectly hold any equity or investment rights in Sichuan Health Pharmaceutical [1] - Sichuan Health Pharmaceutical is not a subsidiary of Tongrentang but is under the Tongrentang Group [1] - The company emphasized that all its medicines are self-produced and that there is no outsourcing to third parties for production [1] Group 2 - Consumers are advised to identify Tongrentang products through the "Tongrentang Shuanglong trademark" and the production unit labeling [1]

Core Viewpoint - The company clarifies its non-ownership of Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. and emphasizes its focus on self-produced traditional Chinese medicine products [1] Group 1 - The company has responded to recent online reports regarding Anhui Habao Pharmaceutical's production and the Antarctic krill oil products associated with the "Tongrentang" brand [1] - The company does not hold any equity in Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., which is a subsidiary of its controlling shareholder, Tongrentang Group [1] - The "Tongrentang" trademark and name are owned by Tongrentang Group, and the company, along with some subsidiaries, is authorized to use them [1] Group 2 - The company emphasizes that it focuses on the production and sale of medicines, with all existing traditional Chinese medicines being self-produced [1] - There is no third-party production involved in the company's products, ensuring quality and brand integrity [1] - The company has communicated with Tongrentang Group regarding the situation to jointly protect brand reputation [1]